Use of abciximab and tirofiban in patients with peripheral arterial occlusive disease and arterial thrombosis.

Abstract

Acute peripheral arterial occlusive disease is an important factor affecting the mobility and mortality rate of elderly patients. Catheter-guided arterial thrombolysis in these patients has its limitations: long lysis times, early occlusions, and high restenosis rates. The study investigated whether the use of tirofiban has the same favorable effect as the glycoprotein (GP) IIb/IIIa receptor antagonist abciximab and whether lysis times can be shortened and the disease course positively influenced by these substances. Sixty patients were randomly assigned to 2 groups. Each group received 5 mg recombinant tissue-type (rt-PA) plasminogen activator by slow intra-arterial injection for 10 minutes followed by 5 mg rt-PA per hour and 500 IU heparin per hour IV. After randomization 1 group received a bolus of 0.25 mg abciximab per kg body weight followed by 10 mg per minute IV for 12 hours (heparin was reduced to 250 IU/hr). The other group received a bolus of 0.4 microg tirofiban per kg body weight as well as postinterventional medication with 0.1 microg tirofiban per minute and kg body weight for 24 hours. During medication with GP IIb/IIIa inhibitor, the patients received a reduced heparin dosage for 24 hours. After 24 hours both groups received 200 mg aspirin orally and full heparinization controlled on the basis of the partial thromboplastin time. The following efficacy criteria were analyzed: rehospitalization events, reintervention events, and amputations within 6 months. Secondary endpoints were changes in the Fontaine stage, the crurobrachial index, the distance to claudication, and the duration of local arterial lysis. No significant differences were found between the abciximab and tirofiban groups in terms of the rehospitalization, reintervention, or amputation rates, nor were there any group differences in the total number of events. The secondary parameters, such as the crurobrachial index, distance to claudication, and Fontaine stage, also showed no significant differences between the 2 groups within 6 months. The duration of lysis was significantly shorter in the abciximab group. Major bleeding events did not occur in either group. With regard to the adverse effect rate, there were no significant differences between the 2 groups. Both abciximab and tirofiban can be used successfully in patients with peripheral arterial occlusive disease and arterial thrombosis.

• Authors: Johannes Schweizer, Wilhelm Kirch, Reiner Koch, Axel Müller, Grit Hellner, Lutz Forkmann
• Journal: Angiology (Angiology) 2003 Mar-Apr Vol. 54 Issue 2 Pg. 155-61 ISSN: 0003-3197 [Print] United States
• PMID: 12678189 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Antibodies, Monoclonal
• Fibrinolytic Agents
• Immunoglobulin Fab Fragments
• Platelet Glycoprotein GPIIb-IIIa Complex
• Tyrosine
• Tissue Plasminogen Activator
• Tirofiban
• Abciximab

Topics

• Abciximab
• Aged
• Antibodies, Monoclonal (therapeutic use)
• Arterial Occlusive Diseases (drug therapy)
• Female
• Fibrinolytic Agents (administration & dosage)
• Humans
• Immunoglobulin Fab Fragments (therapeutic use)
• Male
• Middle Aged
• Pilot Projects
• Platelet Glycoprotein GPIIb-IIIa Complex (antagonists & inhibitors)
• Tirofiban
• Tissue Plasminogen Activator (administration & dosage)
• Tyrosine (analogs & derivatives, therapeutic use)